Vir Biotechnology Faces Challenges but Shows Promise with Hepatitis B Study Results
Vir Biotechnology Inc. navigates turbulent financial waters amidst promising developments in its chronic hepatitis B treatment, with preliminary data from the MARCH study showing potential for its therapeutic candidates.
3 minutes to read